Aurinia Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aurinia Pharmaceuticals generated cash of -$69,858,000, which is less than the previous year. Cash used in financing activities reached the amount of $194,375,000 last year. Net change in cash is therefore -$33,669,000.
Cash Flow
| 2011 | -1.35M | -1.15M | 2.28M |
|---|---|---|---|
| 2012 | -6.54M | -31.16K | 716.70K |
| 2013 | -4.52M | -35.68K | 6.20M |
| 2014 | -16.90M | -10.08M | 47.89M |
| 2015 | -17.76M | -23K | 839K |
| 2016 | -18.71M | 9.99M | 42.61M |
| 2017 | -41.16M | -8.00M | 175.15M |
| 2018 | -51.61M | -66K | 4.01M |
| 2019 | -63.45M | 7.78M | 243.72M |
| 2020 | -69.85M | -156.42M | 194.37M |
AUP.TO Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 306.01M | 117.96M | 165.62M | 39.64M | 5.75M | 22.70M | 1.82M | 172.80K | 6.07M | 6.21M |
Operating activities | ||||||||||
Net income | -102.68M | -123.84M | -64.12M | -70.79M | -23.29M | -18.60M | -16.64M | -2.54M | -9.73M | -2.40M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.37M | 1.54M | 1.56M | 1.45M | 1.47M | 1.55M | 1.52M | 813.32K | 851.40K | 960.82K |
Stock-based compensation expense | 17.45M | 7.41M | 6.86M | 4.24M | 1.38M | 3.22M | 2.18M | 223.52K | 276.42K | 371.20K |
| Deferred income tax benefit | 17.45M | 7.41M | 6.86M | 4.24M | 1.38M | 3.22M | 2.18M | 223.52K | 276.42K | 371.20K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | -23K | -39K | 45K | 9K | 65.74K | 102.53K | -167.48K |
Inventories | -13.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 869K | -1.50M | 1.13M | 2.51M | 0 |
Cash generated by operating activities | -69.85M | -63.45M | -51.61M | -41.16M | -18.71M | -17.76M | -16.90M | -4.52M | -6.54M | -1.35M |
Investing activities | ||||||||||
Purchases Of Investments | -202.95M | 0 | -36.08M | -97.99M | -21.13M | -19.98M | -9.99M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -7.34M | -104K | -75K | -25K | -25K | -50K | -90K | -104.24K | -5.02K | -15.67K |
Acquisitions Net | -154.66M | 0 | 45K | 0 | 10K | 44K | 0 | 3.75K | 0 | 0 |
Cash generated by investing activities | -156.42M | 7.78M | -66K | -8.00M | 9.99M | -23K | -10.08M | -35.68K | -31.16K | -1.15M |
Financing activities | ||||||||||
Common Stock Issued | 187.73M | 223.11M | 0 | 0 | 0 | 0 | 48.30M | 5.86M | 761.93K | 2.29M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -1.6M | -33.81K | -45.23K | -11.75K |
Cash used in financing activities | 194.37M | 243.72M | 4.01M | 175.15M | 42.61M | 839K | 47.89M | 6.20M | 716.70K | 2.28M |
Net Change In Cash | -33.66M | 188.05M | -47.66M | 125.98M | 33.89M | -16.95M | 20.88M | 1.64M | -5.89M | -294.80K |
Cash at end of period | 272.35M | 306.01M | 117.96M | 165.62M | 39.64M | 5.75M | 22.70M | 1.81M | 184.95K | 5.92M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |